Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study
Authors:
Open Access
- 8 October 2025
- journal article
- Published by Wiley in Phytotherapy Research
- Vol. 40 (8) , 4802-4812
Abstract
Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults ( N = 191) aged between 18 and 65 years were included in the study. Clinical assessments were done at baseline, followed by monthly for 12 months, whereas laboratory and other study assessments were done at baseline, 6 and 12 months. The primary outcome was the clinical adverse events reported by the patients, whereas secondary outcomes were Clinical Global Impression—Improvement scale (CGI‐I), health‐related Short Form‐12 Quality of Life (SF‐12 QoL), and laboratory estimations of serum for cortisol, hepatic, renal, and thyroid function. ARE administration for 12 months reported 18 mild adverse events, which were resolved without intervention. The study reported no clinical significant changes in serum alanine transaminases (baseline: 31.31 ± 9.28 IU /L, end of study: 33.68 ± 6.80 IU /L), aspartate transaminases (baseline: 30.61 ± 7.18 IU/L, end of study: 29.02 ± 4.63 IU/L). Serum cortisol levels decreased significantly ( p < 0.001), while lipid profile and plasma glucose levels remained unaffected. Serum testosterone (free and total) significantly increased ( p < 0.05). SF ‐12 scores demonstrated significant improvements at 12 months ( p < 0.001), indicating enhanced health‐related quality of life. CGI assessment indicated overall improvement in 68.7% of patients, particularly notable in those aged ≥ 50 years. This study validates the long‐term safety of ARE use over 12 months. Trial Registration: ClinicalTrials.gov identifier: CTRI/2022/10/046180; NCT06244147.Keywords
This publication has 48 references indexed in Scilit:
- Effects of Root Extract of Ashwagandha (Withania somnifera) on Perception of Recovery and Muscle Strength in Female AthletesEuropean Journal of Sport Science, 2025
- Construct validity of the 12-item Short Form Health Survey (SF-12) version 2 and the impact of lifestyle modifications on the health-related quality of life among Indian adults with prediabetes: results from the D-CLIP trialQuality of Life Research, 2024
- Effect of standardized root extract of ashwagandha (Withania somnifera) on well‐being and sexual performance in adult males: A randomized controlled trialHealth Science Reports, 2022
- A double-blind, randomized, placebo-controlled trial on the effect of Ashwagandha (Withania somnifera dunal.) root extract in improving cardiorespiratory endurance and recovery in healthy athletic adultsJournal of Ethnopharmacology, 2021
- Safety of Ashwagandha Root Extract: A Randomized, Placebo-Controlled, study in Healthy VolunteersComplementary Therapies in Medicine, 2021
- Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled studyJournal of Ethnopharmacology, 2021
- Ashwagandha and Kidney Transplant RejectionKidney International Reports, 2020
- Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailmentsJournal of Ethnopharmacology, 2020
- Cognitive Behavioral Therapy for Early Adolescents With Autism Spectrum Disorders and Clinical Anxiety: A Randomized, Controlled TrialBehavior Therapy, 2015
- The antioxidant and pro-oxidant activities of green tea polyphenols: A role in cancer preventionArchives of Biochemistry and Biophysics, 2010